Skip to main content
SpringerLink
Log in

Abbott has received reimbursement approval in France for its everolimus-eluting coronary stent system

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Abbott.Abbott Gains Reimbursement for XIENCE(TM) V Drug Eluting Stent in France. Media Release: 1 Feb 2008. Available from: URL: http://www.abbott.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abbott has received reimbursement approval in France for its everolimus-eluting coronary stent system. Pharmacoecon. Outcomes News 546, 10 (2008). https://doi.org/10.2165/00151234-200805460-00035

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200805460-00035

Keywords

Search

Navigation